Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB

NCT ID: NCT03350048

Last Updated: 2023-02-01

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 969 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-04-01
• Study Completion Date: 2020-07-31

Brief Summary

Title: Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB (Screen TB)

Introduction: Tuberculosis (TB) places severe pressure on health care services of the developing world. Despite the introduction of the highly sensitive and specific GeneXpert MTB/RIF (GeneXpert) test [1] with a potential turn-around time of two hours, many people in high TB prevalence areas still do not have access to efficient TB diagnostic services due to logistical constraints in these settings. A cost effective, rapid, point-of-care screening test with high sensitivity would identify people with a high likelihood for active TB and would prioritize them for testing with more expensive, technically or logistically demanding assays including GeneXpert or liquid culture, facilitating cost-effective diagnostic work-up in resource-limited settings. A serum cytokine signature for active TB disease, discovered in the AE-TBC project, with a sensitivity of 89% (CI 78 - 95%) and specificity of 76% (CI 68 - 83%), will be optimised and utilized in a point-of-care format (TransDot) to rapidly test for TB disease in symptomatic people.

Hypothesis: The TransDot test will achieve a sensitivity of > 90% for TB disease, in a training set of people suspected of having TB disease, and be validated (achieve similarly high sensitivity) subsequently in a prospective test set of people suspected of having TB disease, when compared to a composite gold standard of sputum culture, smear, GeneXpert, chest X-ray, TB symptoms and TB treatment response.

Objectives: The overall objective of the study is to incorporate a six-marker serum signature into a multiplex UCP-LFA format, referred to as TransDot, for finger-prick blood testing. The end point of the study is the accuracy (sensitivity and specificity) of the UCP-LFA TransDot test on finger-prick blood for active TB and will be prospectively compared against gold standard composite diagnostic criteria (GeneXpert, MGIT culture, TB sputum smear, CXR, TB symptom screen and response to TB treatment).

Primary: The primary outcome of interest will be accuracy, sensitivity and specificity of the TransDot finger-prick test when compared with the composite gold standard tests.

Detailed Description

Protocol Summary Title: Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB (Screen TB)

Population: A total of 800 people presenting at primary health care clinics with presumed active pulmonary tuberculosis, aged 18 to 70 years, male or female gender, will be recruited. They should be willing to give informed, written consent, including consent for HIV testing. They should have symptoms that could be compatible with active TB (cough > two weeks, plus at least one of the following: fever, weight loss, haemoptysis and night sweats). Participants should not have been on TB treatment for the past 90 days and should not have received immune suppressive therapy, be known with alcohol of drug abuse, have a haemoglobin level <9g/dl or be pregnant or breastfeeding. HIV co-infection is not an exclusion criterion. Participants will be recruited from primary health care clinics in Cape Town, South Africa, Windhoek in Namibia, Addis Ababa in Ethiopia, Banjul in The Gambia and Kampala in Uganda.

Number of Sites: Five sites

Study Duration: 3 years

Subject Duration: 18 months for TB cases, 2 months for non-TB cases

Objectives:

The overall objective of the study is to incorporate a six-marker serum signature into a multiplex UCP-LFA format, referred to as TransDot, for finger-prick blood testing. The end point of the study is the accuracy (sensitivity and specificity) of the UCP-LFA TransDot test on finger-prick blood for active TB and will be prospectively compared against gold standard composite diagnostic criteria (GeneXpert, MGIT culture, TB sputum smear, CXR, TB symptom screen and response to TB treatment).

Conditions

Pulmonary Tuberculosis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Training Set

First 500 participants recruited for the Training Set:

• Blood collection for optimization and validation (vs ELISA) of TransDot point-of-care test at LUMC and later for lab-based TransDot at local site laboratory
• Blood, sputum, saliva and urine collection for secondary objectives and repository

No interventions assigned to this group

Test Set

Subsequent 300 participants to be used for the Test Set:

• Fingerprick TransDot point-of-care test performed at field site after symptom screen and clinical evaluation and before CXR
• Blood, sputum, saliva and urine collection for secondary objectives and repository

Trans-Dot point-of-care test

Intervention Type: DIAGNOSTIC_TEST

Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.

Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response.

Interventions

Trans-Dot point-of-care test

Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.

Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Symptoms suggestive of TB disease: cough for more than two weeks with fever, malaise, weight loss, night sweats, haemoptysis, chest pain or loss of appetite.
• Willingness to give consent to take part in the study.
• Willingness to undergo HIV testing or be willing to have their HIV infection status disclosed to the study field workers.
• Eighteen years or older and aged 70 years or younger.

Exclusion Criteria

• Permanent residence in study area for less than 3 months or with no permanent address.
• Pregnancy or breastfeeding.
• HB<9g/l
• On TB treatment currently or in the last ninety days.
• HIV positive patients currently on INH prophylaxis, or in the last ninety days.
• Known quinolone or aminoglicozide antibiotic use reported in the past 60 days.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Armauer Hansen Research Institute, Ethiopia

OTHER

Sponsor Role: collaborator

Medical Research Council Unit, The Gambia

OTHER

Sponsor Role: collaborator

Leiden University Medical Center

OTHER

Sponsor Role: collaborator

Makerere University

OTHER

Sponsor Role: collaborator

London School of Hygiene and Tropical Medicine

OTHER

Sponsor Role: collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

Sponsor Role: collaborator

LINQ Management GMBH

UNKNOWN

Sponsor Role: collaborator

Prof Gerhard Walzl

OTHER

Sponsor Role: lead

Responsible Party

Prof Gerhard Walzl

Prof

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Gerhard Walzl, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Head of Department of Biomedical Sciences

Locations

Armauer Hansen Research Institute

Addis Ababa, , Ethiopia

European Research and Project Office GmbH

Saarbrücken, Saarland, Germany

LINQ Management GmbH

Berlin, , Germany

University of Namibia

Windhoek, , Namibia

The European & Developing Countries Clinical Trials Partnership Association (EDCTP)

The Hague, South Holland, Netherlands

Leiden University Medical Center (Academisch Ziekenhuis Leiden, LUMC)

Leiden, , Netherlands

Stellenbosch University

Cape Town, Western Cape, South Africa

Medical Research Council The Gambia

Banjul, , The Gambia

Makerere University

Kampala, , Uganda

London School of Hygiene and Tropical Medicine

London, , United Kingdom

Countries

Ethiopia; Germany; Namibia; Netherlands; South Africa; The Gambia; Uganda; United Kingdom

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

N16/05/070

Identifier Type: -

Identifier Source: org_study_id